– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

SCHEDULE 13G/A - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

SCHEDULE 13G - Alto Neuroscience, Inc. (0001999480) (Subject)

10-Q - Alto Neuroscience, Inc. (0001999480) (Filer)

8-K - Alto Neuroscience, Inc. (0001999480) (Filer)

DEFR14A - Alto Neuroscience, Inc. (0001999480) (Filer)

DEFA14A - Alto Neuroscience, Inc. (0001999480) (Filer)

DEF 14A - Alto Neuroscience, Inc. (0001999480) (Filer)

S-8 - Alto Neuroscience, Inc. (0001999480) (Filer)

Wedbush downgraded Alto Neuroscience from Outperform to Neutral and set a new price target of $4.00 from $29.00 previously

Rodman & Renshaw downgraded Alto Neuroscience from Buy to Neutral

Wedbush initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $29.00

William Blair initiated coverage of Alto Neuroscience with a rating of Outperform

TD Cowen initiated coverage of Alto Neuroscience with a rating of Outperform

Robert W. Baird initiated coverage of Alto Neuroscience with a rating of Outperform and set a new price target of $32.00

Jefferies initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $33.00

Stifel initiated coverage of Alto Neuroscience with a rating of Buy and set a new price target of $32.00

– ALTO-207 (fka CTC-501) is a fixed-dose combination of pramipexole and ondansetron designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole – – Alto has generated proprietary insights on dopamine biomarkers in depression suggesting that direct dopamine receptor activation with ALTO-207 has the potential to be a differentiated therapeutic approach for treatment resistant depression (TRD) – – CTC-501 met primary and secondary endpoints in a completed Phase 2a study in MDD, demonstrating significantly greater improvements on MADRS compared to placebo (Week 8 Cohen's d = 1.1, p<0.05) – – Alto expects to initiate a Phase 2b trial, design

– Convergent clinical and preclinical evidence supports the mechanistic link between ALTO-300 and the biomarker, a measure of greater EEG irregularity, being used for patient selection – – Completed Phase 2a and ongoing Phase 2b trial of ALTO-300 in MDD underscore favorable tolerability profile for 25mg dose – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced a presentation at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, in Scottsdale, Arizona, held May 27-30, 2025. ALTO-300, also known as agomelatine, is an oral, s

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in June: Jefferies Global Healthcare Conference, June 3-5th 2025: Format: Fireside chat and one-on-one investor meetings Presentation Date/Time: Thursday, June 5, 2025, at 2:00 pm ET Location: New York Marriott Marquis H.C. Wainwright 6th Annual Neuro Perspectives Conference, June 16-17th 2025: Format: Fireside chat and one-on-one investor meetings Presentation avail

– Phase 2 proof-of-concept trials remain on track: Topline data expected from ALTO-203 in MDD in the second quarter of 2025 followed by ALTO-101 in schizophrenia in the second half of 2025 – – Late-stage programs advancing: Topline data expected from the Phase 2b trial of ALTO-300 in MDD in mid-2026 followed by the Phase 2b trial of ALTO-100 in bipolar depression in the second half of 2026 – – New data presented at recent scientific conferences support Alto's biomarker-driven pipeline and patient stratification approach – – Strong cash position of approximately $161.3 million expected to fund planned operations into 2028, and through at least four upcoming clinical study readouts – Alto

– Identified and prospectively replicated an EEG-based biomarker for placebo response in MDD – – New data strengthen the mechanistic link between ALTO-300 and the EEG biomarker being used for patient selection; biomarker signature induced by activating 5-HT2C or depleting dopamine directly – – Preclinical ALTO-101 rescue study underscores the therapeutic potential of this novel PDE4 inhibitor, and validates EEG theta response as a robust translational biomarker for CIAS – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced multiple presentations at t

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the JonesResearch Virtual CNS Day on Tuesday, April 29, 2025, at 12:30 pm ET and participate in one-on-one investor meetings. The presentation will be accessible via a live webcast on the Events and Presentations page in the Investors section of Alto's website and a replay will be available following the presentation. About Alto Neuroscience Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiat

– Favorable outcome from interim analysis of ongoing ALTO-300 Phase 2b MDD trial; topline results expected in mid-2026 – – Completed enrollment in ALTO-203 Phase 2 proof-of-concept MDD trial; on track to report topline data in the second quarter of 2025 – – Novel transdermal formulation of ALTO-101 demonstrated greater drug exposure and improved tolerability profile; topline data from Phase 2 trial of ALTO-101 in schizophrenia expected in the second half of 2025 – – Company's precision psychiatry approach underpins recently granted patents covering the use of ALTO-100 and ALTO-300 in biomarker defined populations – – Strong cash position of approximately $169 million expected to fund pl

SINGAPORE, March 13, 2025 /PRNewswire/ -- High-Trend International Group (NASDAQ:HTCO) (the "Company"), an international shipping company, today announced the appointment of Christopher Nixon Cox, as Chairman of the Company, effective immediately. Mr. Cox , a venture capitalist and advocate for socially impactful investing, will leverage his extensive expertise in global markets and sustainability to drive the Company's strategic growth in innovation-driven sectors. Mr. Jinyu Chang resigned as Chairman while remaining a director of the Company. The Company also named Mr. Bo Cui as its new Chief Legal Officer, underscoring its commitment to strengthening governance and global compliance amid

Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company management team will present at the following upcoming investor conferences and events in March: TD Cowen 45th Annual Health Care Conference, March 3-5th 2025: Format: Presentation and one-on-one investor meetings Presentation Date/Time: Tuesday, March 4, 2025, at 9:50 am ET Location: Marriott Copley Place, Boston, MA Leerink's Global Healthcare Conference 2025, March 10-12th 2025: Format: Presentation and one-on-one investor meetings Presentation Date

– Patent supports Alto's precision approach to improve patient selection – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Patent and Trademark Office has granted U.S. Patent Number 12,226,375, with method claims pertaining to treatment of major depressive disorder (MDD) in patients with inadequate response to an antidepressant. The method includes treatment with ALTO-300 as an adjunctive therapy and patient selection using specific electroencephalogram (EEG) measures. As granted, not accounting for any potential patent term extension